Objective: The aim of this study is to review research examining an immunological basis for chronic fatigue syndrome (CFS) and to discuss how a disturbance in immunity could produce central nervous system (CNS)-mediated symptoms. Method: Data relevant to the hypothesis that abnormal cytokine release plays a role in the pathogenesis of CFS are reviewed as well as recent evidence relating to potential mechanisms by which immune products may enter the brain and produce a disturbance in CNS processes.
Results: Examinations of cytokine levels in patients with CFS have produced inconclusive results. Recent evidence suggests that abnormal release of cytokines within the CNS may cause neural dysfunction by a variety of complex mechanisms.
Conclusion: Neuropsychiatric symptoms in patients with CFS may be more closely related to disordered cytokine production by glial cells within the CNS than to circulating cytokines. This possibility is discussed in the context of unresolved issues in the pathogenesis of CFS.
LloydAHickieIWakefieldD.Immunity and the pathophysiology of chronic fatigue syndrome. Ciba Foundation Symposium1993; 173:176–192.
2.
FukudaKStrausSEHickieISharpeMCDobbinsJGKomaroffA.The chronic fatigue syndrome: a comprehensive approach to its definition and study. Annals of Internal Medicine1994; 121:953–959.
3.
DickinsonCJChronic fatigue syndrome–aetiological aspects. European Journal of Clinical Investigation1997; 27:257–267.
4.
HickieILloydAHadzi-PavlovicDParkerGBirdKWakefieldD.Can the chronic fatigue syndrome be defined by distinct clinical features. Psychological Medicine1995; 25:925–935.
5.
WhitePDThomasJMAmessJGraverSAKangroHOClareAWThe existence of a fatigue syndrome after glandular fever. Psychological Medicine1995; 25:907–916.
6.
HotopfMNoahNWesselyS.Chronic fatigue and minor psychiatric morbidity after viral meningitis: a controlled study. Journal of Neurology, Neurosurgery and Psychiatry1996; 60:504–509.
7.
HickieIBHookerAWHadzi-PavlovicDBennettBKWilsonAJLloydARFatigue in selected primary care settings; sociodemographic and psychiatric correlates. Medical Journal of Australia1996; 64:585–588.
8.
KantonWWalkerEAThe relationship of chronic fatigue to psychiatric illness in community, primary care and tertiary care samples. Ciba Foundation Symposium1993; 173:193–204.
9.
WesselySChalderTHirschSPawlikowskaTWallacePWrightDJMPostinfectious fatigue: prospective cohort study in primary care. Lancet1995; 345:1333–1338.
10.
DaughertySAHenryBPetersonDLSwartsRLBastienSThomasRSChronic fatigue syndrome in northern Nevada. Reviews of Infectious Diseases1991; 13:s39–s44.
KonstantinovKvon MikeczABuchwaldDJonesJGeraceLTanEMAutoantibodies to nuclear envelope antigens in chronic fatigue syndrome. Journal of Clinical Investigations1996; 98:1888–1896.
13.
ChaoCCJanoffENHuSAltered cytokine release in peripheral blood mononuclear cell cultures from patients with the chronic fatigue syndrome. Cytokine1991; 3:292–298.
14.
RenaultPFHoofnagelJHSide effects of alpha interferon. Seminars in Liver Disease1989; 9:273–277.
15.
HartB.Biological basis of the behaviour of sick animals. Neuroscience and Biobehavioral Reviews1988; 12:123–137.
16.
DantzerRBlutheRMKentSKellyKWBehavioural effects of cytokines. In: RothwellNJDantzerR, eds. Interleukin-1 in the brain. Oxford: Pergamon Press, 1992.
17.
LloydAHannaD AbiWakefieldD.Interferon and myalgic encephalomyelitis. Lancet1988; i:471.
18.
LloydAHickieIBrockmanADwyerJWakefieldD.Serum and cerebrospinal fluid cytokine levels in patients with chronic fatigue syndrome and control subjects. Journal of Infectious Diseases1991; 164:1023–1024.
19.
LloydAGandeviaSBrockmanAHalesJWakefieldD.Cytokine production and fatigue in patients with chronic fatigue syndrome and healthy control subjects in response to exercise. Clinical Infectious Diseases1994; 18:s142–s146.
20.
LindeAAnderssonBSvensonSBSerum levels of lymphokines and soluble cellular receptors in primary Epstein-Barr virus infection and in patients with chronic fatigue syndrome. Journal of Infectious Diseases1992; 165:994–1000.
21.
PatarcaRKlimasNCLugtendorfSAntoniMFletcherMADysregulated expression of tumor necrosis factor in chronic fatigue syndrome: interrelations with cellular sources and patterns of soluble immune mediator expression. Clinical Infectious Diseases1994; 18:s147–s153.
22.
LeverAMLLewisDMBannisterBAFryMBerryN.Interferon production in postviral fatigue syndrome. Lancet1988; i: 101.
23.
SwaninkCMVercoulenJHMMGalamaJMDLymphocyte subsets, apoptosis, and cytokines in patients with chronic fatigue syndrome. Journal of Infectious Diseases1996; 173:460–463.
24.
BanksWAKastinAJGutierrezEGInterleukin-1 alpha in blood has direct access to cortical brain cells. Neuroscience Letters1993; 163:41–44.
25.
HickeyWFT-lymphocyte entry and antigen recognition in the central nervous system. In: AderRFeltenDLCohenN, eds. Psychoneuroimmunology. 2nd ed.San Diego, CA: Academic Press, 1991:149–175.
26.
ChungIYBenvenisteENTumor necrosis factor-alpha production by lipopolysaccharide, INF-gamma, and IL-1-beta. Journal of Immunology1990; 144:2999–3007.
27.
MalipieroUVFreiKFontanaA.Production of hemopoietic colony-stimulating factors by astrocytes. Journal of Immunology1990; 144:3816–3821.
28.
SharifSFHaririRJChangVABariePSWangRSGhajarJBGHuman astrocyte production of tumor necrosis factor-alpha, interlekin-1 beta, and interleukin-6 following exposure to lipopolysaccharide endotoxin. Neurological Research1993; 15:109–112.
29.
SmithCADavisTAndersonDA receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science1990; 248:1019–1023.
30.
SchonbitzBde KloetERSutantoWHolsboerF.Cellular localization of interleukin-6 mRNA and interleukin-6 receptor mRNA in rat brain. European Journal of Neuroscience1993; 5:1426–1435.
31.
ShintaniFKanbaSNakakiTInterleukin-1 beta augments release of norepinepherine, dopamine, and serotonin in the rat anterior hypothalamus. Journal of Neuroscience1993; 13:3574–3581.
32.
ZalcmanSGreen-JohnsonJMMurrayLNanceDMDyckDAnismanHGreebgergAHCytokine-specific central monoamine alterations induced by interleukin−1, −2 and −6. Brain Research1994; 643:40–49.
33.
OitzlMSvan OersHSchobitzBde KloetERInterleukin-1 beta but not interleukin-6 impairs spatial navigation learning. Brain Research1993; 613:160–163.
34.
BianchiMFerrarioPZontaNPaneraiAEEffects of interleukin-1 beta and interleukin-2 on amino acid levels in mouse cortex and hippocampus. NeuroReport1995; 6:1689–1692.
35.
EpsteinLGGendelmanHEHuman immunodeficiency virus type 1 infection of the nervous system: pathogenic mechanisms. Annals of Neurology1993; 33:429–436.
36.
VandenabeelePFiersW.Is amyloidogenesis during Alzheimer's disease due to IL-1/IL-6 mediated ‘acute phase response’ in the brain?Immunology Today1991; 12:217–219.
37.
ChaoCCHuSTsangMEffects of transforming growth factor-beta on murine astrocyte glutamine synthetase activity. Implications in neural injury. Journal of Clinical Investigation1992; 90:1786–1793.
38.
ChoiDWGlutamate neurotoxicity and diseases of the nervous system. Neuron1988; 1:623–634.
39.
FontanaAConstamDBFreiKMalipieroUPfisterHWModulation of the immune response by transforming growth factor beta. International Archives of Allergy and Immunology1992; 99:1–7.
40.
BuchwaldDCheneyPRPetersonDLA chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpes virus type 6 infection. Annals of Internal Medicine1992; 116:103–113.
41.
IchiseMSalitIEAbbeySEAssessment of regional cerebral perfusion by 99Tcm-HMPAO SPECT in chronic fatigue syndrome. Nuclear Medicine Communications1992; 13:767–772.
42.
AderRFeltenDLCohenN, eds. Psychoneuroimmunology. San Diego, CA: Academic Press, 1991.
